Trial Profile
An observational, retrospective, multicenter study to evaluate the efficacy and safety of abacavir/lamivudine (Kivexa) plus rilpivirine in naive HIV-1 infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2016
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms KiRilNa
- 02 Sep 2016 Results assessing efficacy and safety of Abacavir/Lamivudine plus Rilpivirine published in the Journal of Antimicrobial Chemotherapy (2016).
- 02 Mar 2016 New trial record